Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Rhodamine 6G. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.36 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.36 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.35 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rhodamine 6G SCHEMBL23064835 | 1.00 | USP2 (0.38) | USP2CFTRPAX8ATMGOPC | |
| Rhodamine 6G SCHEMBL5606069 | 1.00 | USP2 (0.38) | USP2CFTRPAX8ATMGOPC | |
| Rhodamine 6G SCHEMBL58076 | 1.00 | USP2 (0.38) | USP2CFTRPAX8ATMGOPC | |
| Rhodamine 6G SCHEMBL15348373 | 1.00 | USP2 (0.38) | USP2CFTRPAX8ATMGOPC | |
| Rhodamine 6G SCHEMBL23064834 | 1.00 | USP2 (0.38) | USP2CFTRPAX8ATMGOPC | |
| Rhodamine 6G SCHEMBL8647391 | 0.99 | USP2 (0.38) | USP2CFTRPAX8ATMGOPC | |
| Rhodamine 6G SCHEMBL10028465 | 0.99 | ABCB1 (0.38) | USP2CFTRPAX8ATMGOPC | |
| Rhodamine 6G SCHEMBL1495836 | 0.99 | ABCB1 (0.38) | USP2CFTRPAX8ATMGOPC | |
| Rhodamine 6G SCHEMBL4817749 | 0.99 | ABCB1 (0.38) | USP2CFTRPAX8ATMGOPC | |
| Rhodamine 6G SCHEMBL4218403 | 0.98 | USP2 (0.37) | USP2CFTRPAX8ATMGOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116284021-B | Compounds having therapeutic effect on bladder cancer | 湖南大学 | 2024-04-02 | — | — | CN | claimed |
| CN-116284021-A | Compounds having therapeutic effect on bladder cancer | 湖南大学 | 2023-06-23 | — | — | CN | claimed |
| EP-4704933-A1 | DEVICES AND METHODS FOR PREPARING AND CONDITIONING BIOLOGICAL ASSEMBLIES FOR MINIMALLY INVASIVE DELIVERY FOR TISSUE ENGINEERING, CELL THERAPIES AND OTHER THERAPEUTIC APPLICATIONS | Volumina Medical SA (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-12391981-B2 | Chromogenic peroxidase substrates | AGILENT TECHNOLOGIES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| WO-2024227265-A1 | DEVICES AND METHODS FOR PREPARING AND CONDITIONING BIOLOGICAL ASSEMBLIES FOR MINIMALLY INVASIVE DELIVERY FOR TISSUE ENGINEERING, CELL THERAPIES AND OTHER THERAPEUTIC APPLICATIONS | VOLUMINA MEDICAL SA (CH) | 2024-11-07 | — | — | WO | disclosed |
| US-20240360495-A1 | CHROMOGENIC PEROXIDASE SUBSTRATES | DAKO DENMARK APS (DK) | 2024-10-31 | — | — | US | disclosed |
| US-11993810-B2 | Chromogenic peroxidase substrates | AGILENT TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-116284021-B | Compounds having therapeutic effect on bladder cancer | 湖南大学 | 2024-04-02 | — | — | CN | disclosed |
| CN-116284021-B | Compounds having therapeutic effect on bladder cancer | 湖南大学 | 2024-04-02 | — | — | CN | disclosed |
| EP-4336184-A2 | CHROMOGENIC PEROXIDASE SUBSTRATES | Agilent Technologies, Inc. (A Delaware Corporation) (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3391056-B1 | CHROMOGENIC PEROXIDASE SUBSTRATES | AGILENT TECHNOLOGIES INC (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3007705-A1 | SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES | ONCOIMMUNIN, INC. (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014201306-A1 | SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES | ONCOIMMUNIN, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-7205045-B2 | Devices for calibrating optical scanners and methods of using the same | AGILENT TECHNOLOGIES, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20050137280-A1 | Devices for calibrating optical scanners and methods of using the same | HOLCOMB NELSON R (US) | 2005-06-23 | — | — | US | disclosed |
| US-6794424-B2 | Devices for calibrating optical scanners and methods of using the same | AGILENT TECHNOLOGIES, INC. | 2004-09-21 | — | — | US | disclosed |
| US-20030105195-A1 | Devices for calibrating optical scanners and methods of using the same | AGILENT TECHNOLOGIES, INC. | 2003-06-05 | — | — | US | disclosed |
| EP-0579237-B1 | PS plate and method for processing same | FUJI PHOTO FILM CO LTD (JP) | 1999-05-06 | — | — | EP | disclosed |
| US-5464724-A | Lithography | FUJI PHOTO FILM CO., LTD. (JP) | 1995-11-07 | — | — | US | disclosed |
| EP-0579237-A2 | PS plate and method for processing same | FUJI PHOTO FILM CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360495-A1 | CHROMOGENIC PEROXIDASE SUBSTRATES | MPO, TPO, TYR | GAA 114/4885GLA 423/4885HSP90AA1 3334/4885 |
| US-11993810-B2 | Chromogenic peroxidase substrates | MPO, TPO, TYR | GAA 114/4885GLA 423/4885HSP90AA1 3334/4885 |
| US-12391981-B2 | Chromogenic peroxidase substrates | MPO, TPO, TYR | GAA 114/4885GLA 423/4885HSP90AA1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.